Spruce Biosciences, Inc. (SPRB) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -47.83M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 28.85M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-47.83M | (m) | (m) | $28.85M | (m) | (m) |
| 2026-03-31 | $-34.01M | (m) | (m) | $16.26M | (m) | (m) |
| 2025-12-31 | $-36.51M | $0.00 | (m) | $19.52M | (m) | (m) |
| 2025-09-30 | $-49.49M | $697.00K | (m) | $36.88M | (m) | -7100.00% |
| 2025-06-30 | $-50.67M | $1.30M | (m) | $38.42M | (m) | -3900.38% |
| 2025-03-31 | $-58.01M | $2.91M | (m) | $46.94M | (m) | -1994.16% |
| 2024-12-31 | $-56.15M | $4.91M | (m) | $46.42M | (m) | -1143.37% |
| 2024-09-30 | $-43.24M | $7.10M | (m) | $36.06M | (m) | -608.94% |
| 2024-06-30 | $-47.49M | $9.57M | (m) | $43.00M | (m) | -496.15% |
| 2024-03-31 | $-51.43M | $10.13M | (m) | $48.04M | (m) | -507.82% |
| 2023-12-31 | $-51.99M | $10.09M | (m) | $49.43M | (m) | -515.34% |
| 2023-09-30 | $-52.94M | (m) | (m) | $47.17M | (m) | (m) |
| 2023-06-30 | $-50.84M | (m) | (m) | $42.47M | (m) | (m) |
| 2023-03-31 | $-48.75M | (m) | (m) | $38.40M | (m) | (m) |
| 2022-12-31 | $-47.28M | (m) | (m) | $35.20M | (m) | (m) |
| 2022-09-30 | $-44.31M | (m) | (m) | $32.62M | (m) | (m) |
| 2022-06-30 | $-44.15M | (m) | (m) | $32.43M | (m) | (m) |
| 2022-03-31 | $-43.98M | (m) | (m) | $32.49M | (m) | (m) |
| 2021-12-31 | $-42.07M | (m) | (m) | $30.70M | (m) | (m) |
| 2021-09-30 | $-41.27M | (m) | (m) | $30.25M | (m) | (m) |
| 2021-06-30 | $-39.42M | (m) | (m) | $29.41M | (m) | (m) |
| 2021-03-31 | $-34.10M | (m) | (m) | $25.96M | (m) | (m) |
| 2020-12-31 | $-29.42M | (m) | (m) | $23.85M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-13.11M | (m) | (m) | $10.82M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |